At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)

NCT04270942 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG: teplizumab 1 mg/mL

Sponsor

Provention Bio, a Sanofi Company